Understanding VIP
Understanding VIP
Compound Name
Vasoactive Intestinal Peptide (VIP)
Compound Type
Naturally occurring 28-amino-acid neuropeptide.
Mechanism of Action
Acts mainly through VPAC1 and VPAC2 receptors and participates in vasodilation, smooth-muscle relaxation, intestinal secretion, and immune signalling.
Reported Administration Routes
Intranasal and subcutaneous routes are discussed in research and clinical-practice contexts. Intravenous aviptadil has also been investigated in clinical trials.
Research Monitoring
Source discussions emphasise pancreatic lipase measurements and abdominal symptoms. These suggestions are not a validated universal monitoring protocol.
Research Areas
Vascular physiology, pulmonary research, immune signalling, respiratory conditions, and selected inflammatory-disease research contexts.
Important Evidence Limitation
VIP’s biological activity does not establish clinical effectiveness for every proposed application. Evidence from intravenous aviptadil studies cannot automatically be applied to intranasal or subcutaneous VIP. The routes, formulations, study populations, and clinical outcomes are different.
VIP Reported Dose Patterns
The source describes several subcutaneous and intranasal patterns reported in clinical-practice or research discussions. These figures are included only to document what has been reported. They are not validated dosing recommendations, and no standardised loading, cycling, or washout schedule has been established for general VIP use.
SC example
Per administration
Frequency
Daily total
Reported cycle
Reported Subcutaneous Initial Context
50 mcg/day (source-reported example)
Source describes daily administration in its reported context; this is not a validated clinical schedule.
Not Established
The source describes a 50 mcg/day subcutaneous example over an initial one-to-two-week period. This is a reported practice pattern, not a validated treatment schedule.
Reported Subcutaneous Frequency Variations
100–200 mcg (source-reported examples)
Source describes once or twice daily, or five times weekly in separate reported patterns. These patterns have not been established as safe or effective regimens.
Not Established
Other source-reported subcutaneous examples include 100 mcg once or twice daily, 200 mcg once or twice daily, and 200 mcg five times weekly. These variations do not establish an approved dose range or standard treatment cycle.
Reported Intranasal Context
Approximately 50 mcg per spray (source-reported example)
Spray frequency is not established as a universal clinical protocol.
Not Established
An intranasal example of approximately 50 mcg per spray is mentioned in the source. No validated universal nasal schedule, loading phase, or treatment duration is established.
Reported Subcutaneous Initial Context
Per administration
50 mcg/day (source-reported example)
Frequency
Source describes daily administration in its reported context; this is not a validated clinical schedule.
Daily total
Not Established
Reported cycle
The source describes a 50 mcg/day subcutaneous example over an initial one-to-two-week period. This is a reported practice pattern, not a validated treatment schedule.
Reported Subcutaneous Frequency Variations
Per administration
100–200 mcg (source-reported examples)
Frequency
Source describes once or twice daily, or five times weekly in separate reported patterns. These patterns have not been established as safe or effective regimens.
Daily total
Not Established
Reported cycle
Other source-reported subcutaneous examples include 100 mcg once or twice daily, 200 mcg once or twice daily, and 200 mcg five times weekly. These variations do not establish an approved dose range or standard treatment cycle.
Reported Intranasal Context
Per administration
Approximately 50 mcg per spray (source-reported example)
Frequency
Spray frequency is not established as a universal clinical protocol.
Daily total
Not Established
Reported cycle
An intranasal example of approximately 50 mcg per spray is mentioned in the source. No validated universal nasal schedule, loading phase, or treatment duration is established.
VIP has no universally validated self-administration protocol. The listed amounts are source-reported examples only. Different routes and formulations cannot be assumed equivalent. Pancreatic lipase monitoring, as discussed in the source, does not establish that a particular dose or schedule is safe.
Not a Validated Treatment Protocol
Do not interpret community or clinic-reported patterns as medical instructions. Human evidence for intranasal and subcutaneous VIP remains limited. Any clinical consideration requires a qualified healthcare professional, an appropriate formulation, and route-specific safety assessment.
VIP Safety Considerations
VIP has vasoactive and smooth-muscle effects that can influence blood pressure and other physiological processes. Reported concerns include flushing, hypotension, headache, and possible pancreatic-related issues. Safety information from intravenous aviptadil research should not be assumed to establish the safety of other VIP formulations or administration routes.
VIP Storage Guidelines
Source-Reported Storage
The reference source describes mixed VIP material as requiring cold storage and protection from light. This is a source-reported handling context, not a universal validated storage specification.
Temperature Requirements
Exact storage temperatures and stability periods depend on the specific formulation and manufacturer data. Follow verified product documentation rather than assuming one temperature applies to every preparation.
After Reconstitution
No universal post-reconstitution stability period is established for all VIP preparations. Chemical stability can depend on pH, temperature, concentration, and formulation characteristics.
Research Material Handling
Research-use VIP material should not be assumed equivalent to a validated pharmaceutical product. Preparation quality, peptide identity, sterility, aggregation, and stability require appropriate analytical evidence.
VIP Concentration Calculator Reference
The following example demonstrates basic concentration arithmetic using an assumed amount and final volume. It is an educational calculation only, not a mixing, reconstitution, measurement, or administration instruction.
Amount (mg)
Final volume (mL)
Concentration (mg/mL)
Per 1 U (mcg)
Per 10 U (mcg)
Not Applicable
Not Applicable
Not Applicable
Not Applicable
Not Applicable
Concentration (mg/mL)
3.333
Amount (mg)
Not Applicable
Final volume (mL)
Not Applicable
Concentration (mg/mL)
Not Applicable
Per 1 U (mcg)
Not Applicable
Per 10 U (mcg)
Not Applicable
This mathematical example uses 10 mg divided by an assumed final volume of 3 mL, producing approximately 3.333 mg/mL. Using a U-100 volume marking, where 1 U represents 0.01 mL, the calculated amount is approximately 33.33 mcg per U and 333.3 mcg per 10 U. These are mathematical conversions only and do not provide instructions for preparing or administering VIP. Actual product concentration, formulation, and handling must be independently verified.
VIP Clinical Research Findings
VIP and its synthetic form, aviptadil, have been investigated in different clinical contexts. Evidence from intravenous aviptadil studies must be distinguished from proposed nasal and subcutaneous applications. Research findings in one route or disease setting do not establish effectiveness for unrelated wellness or inflammatory conditions.
28-Amino-Acid Peptide
VIP is a 28-amino-acid neuropeptide involved in several physiological processes, including vascular relaxation, intestinal secretion, and immune signalling.
TESICO Clinical Trial
The TESICO study investigated intravenous aviptadil in critically ill patients with COVID-19-associated respiratory failure. The major trial did not establish a clear improvement in its primary clinical outcome. These findings relate to intravenous aviptadil in a specific hospital setting, not to every VIP formulation or route.
Nasal & Subcutaneous Evidence
Clinical evidence supporting proposed intranasal and subcutaneous VIP wellness protocols remains limited. Evidence from a small study, an uncontrolled report, or a different administration route cannot establish a general treatment benefit.
VIP Approval & Regulatory Status
No Standalone FDA-Approved VIP Product
VIP and aviptadil do not have a standalone FDA-approved product for general wellness or the proposed nasal and subcutaneous protocols. An FDA briefing document has discussed VIP’s compounding status and identified insufficient clinical evidence for certain proposed uses. It also records that aviptadil combined with phentolamine has been approved in some other countries for a specific erectile-dysfunction indication. That combination product is not equivalent to standalone VIP nasal or subcutaneous preparations. Regulatory status and permitted uses vary by country and should be checked against current official records.
This page is for educational and research reference purposes only. It does not provide medical advice, diagnosis, or treatment recommendations. Reported VIP patterns are not validated personal dosing instructions. Clinical decisions should be made with a qualified healthcare professional using reliable product and safety information.
